Value Partners Investments Inc. Purchases New Position in Pfizer Inc. $PFE

Value Partners Investments Inc. bought a new position in Pfizer Inc. (NYSE:PFE) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 164,000 shares of the biopharmaceutical company’s stock, valued at approximately $4,177,000.

Several other hedge funds have also modified their holdings of PFE. Brighton Jones LLC grew its position in Pfizer by 1,282.4% in the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC grew its holdings in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after purchasing an additional 2,087 shares in the last quarter. Campbell & CO Investment Adviser LLC increased its stake in Pfizer by 661.1% during the 1st quarter. Campbell & CO Investment Adviser LLC now owns 57,766 shares of the biopharmaceutical company’s stock worth $1,464,000 after buying an additional 50,176 shares during the period. WCG Wealth Advisors LLC increased its stake in Pfizer by 38.2% during the 1st quarter. WCG Wealth Advisors LLC now owns 77,538 shares of the biopharmaceutical company’s stock worth $1,965,000 after buying an additional 21,431 shares during the period. Finally, PKS Advisory Services LLC boosted its position in Pfizer by 7.0% in the 1st quarter. PKS Advisory Services LLC now owns 13,044 shares of the biopharmaceutical company’s stock valued at $327,000 after buying an additional 849 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on PFE shares. Scotiabank assumed coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price on the stock. Bank of America cut their target price on Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Citigroup started coverage on Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. The Goldman Sachs Group restated a “neutral” rating and issued a $26.00 price target on shares of Pfizer in a research note on Wednesday, November 5th. Finally, HSBC reiterated a “buy” rating and set a $29.00 price objective on shares of Pfizer in a research note on Wednesday, December 10th. Two investment analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $28.06.

Key Stores Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Recent quarterly fundamentals: Pfizer beat consensus on EPS in its last report (reported $0.87 vs $0.79 est.), showing continued profitability that supports the dividend and valuation multiple despite revenue pressure.
• Neutral Sentiment: FY‑2025 guidance trimmed/tightened: Pfizer set EPS guidance of $3.00–$3.15, slightly below consensus (~$3.15), and gave revenue guidance of ~$62.0B vs. street ~$62.6B — a modest miss that reduces upside but doesn’t imply a large earnings shock.
• Neutral Sentiment: Analyst/market commentary is weighing both developments — some pieces ask whether the Hympavzi death plus lower guidance reframes Pfizer’s risk/reward profile rather than proving a definitive business impairment. Article Title
• Neutral Sentiment: Intraday market reaction noted: coverage reports Pfizer stock sliding in recent sessions as traders digest the safety news and guidance. Article Title
• Negative Sentiment: Patient death in Hympavzi hemophilia study: Pfizer reported a death after serious side effects in a long‑term marstacimab/Hympavzi study, prompting an internal safety review and reassessment of surgical protocols — a near‑term clinical and regulatory overhang for the program. Article Title
• Negative Sentiment: Multiple media reports amplify safety concerns and could pressure sentiment until the company provides clear findings from the review; see additional reporting. Article Title

Pfizer Price Performance

PFE opened at $24.89 on Wednesday. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62. The company’s 50-day moving average price is $25.12 and its 200 day moving average price is $24.88. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The firm has a market cap of $141.49 billion, a price-to-earnings ratio of 14.47 and a beta of 0.46.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be given a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 annualized dividend and a dividend yield of 6.9%. Pfizer’s dividend payout ratio is currently 100.00%.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.